Borosilicate glass with UV-blocking properties for pharmaceutical packaging

Information

  • Patent Grant
  • 7951312
  • Patent Number
    7,951,312
  • Date Filed
    Wednesday, April 29, 2009
    15 years ago
  • Date Issued
    Tuesday, May 31, 2011
    13 years ago
Abstract
The borosilicate glass for pharmaceutical packaging has a transmission τ in the visible range of more than 80% at a wavelength of 400 nm, a transmission τ in the UV range of at most 0.1% at wavelengths under 260 nm (each at a sample thickness of 1 mm), a transformation temperature Tg of 550° C. to 590° C. and a processing temperature VA of 1100° C. to 1200° C. The glass has a composition, in wt. % on an oxide basis, of SiO2, 60-80; B2O3, 5-15; Al2O3, 2-10; TiO2, 0.5-7; Σ Li2O+K2O+Na2O, 3-10; Σ alkaline earth oxides, 0.5-10; ZrO2, 0-3; and Fe2O3, 0-0.2. The glass is suitable for packaging UV-sensitive substances but nevertheless permits optical quality control.
Description
CROSS-REFERENCE

The invention claimed and described herein below is also described in German Patent Application DE 10 2008 001 496.6 filed on Apr. 30, 2008 in Germany. The aforesaid German Patent Application provides the basis for a claim of priority of invention for the invention claimed herein below under 35 U.S.C. 119 (a) to (d).


BACKGROUND OF THE INVENTION

1. The Field of the Invention


The subject matter of the present invention is a borosilicate glass with UV-blocking properties for pharmaceutical applications.


2. The Related Art


On account of its good chemical resistance borosilicate glass belongs to the preferred packing materials for pharmaceutical preparations with demanding packaging requirements. Light sensitive, i.e. UV-sensitive, substances are currently packaged in containers made from brown glass, in which the brown color is produced by considerably amounts of iron compounds.


However these strongly colored glasses are only suitable to a limited extent for the optical production control systems increasingly employed by the pharmaceutical industry.


SUMMARY OF THE INVENTION

It is an object of the present invention to provide a colorless physiologically unobjectionable glass, which has the highest water resistance class, a light transmission (at 400 nm) of more than 80 percent in the visible range and a transmission of under 0.1 percent in the UV range at wavelengths under 260 nm.


It is another object of the present invention to provide a glass and/or glass tubing, which is processed in the conventional automated ampoules or bottle-making apparatus and also has a glass transition temperature Tg of about 550° C. to 580° C. and a processing temperature of about 1100 to 1200° C. at a viscosity of 104 dPa s.


The borosilicate glass with UV-blocking properties for pharmaceutical packaging according to the invention has a content, in wt. % on the basis of oxide content, of:




















SiO2
60-80




B2O3
5-15




Al2O3
2-10




TiO2
0.5-7




Σ Li2O + K2O + Na2O
3-10




Σ alkaline earth oxides
0.5-10




ZrO2
0-3




Fe2O3
0-0.2; and











a glass transition temperature Tg of 550° C. to 590° C. and a processing temperature VA of 1100° C. to 1200° C. at a viscosity of 104dPa s, a transmission π of at least 80% at a wavelength of 400 nm, and a transmission π of less than 0.1% at a wavelength of under 260 nm, each transmission being the transmission of a sample with a thickness of 1 mm.


The orosilicate glass may also contain up to 1 wt. % of F in order to improve the viscosity behavior and is made by melting under oxidizing conditions


The TiO2 content is responsible for the UV-blocking. In preferred embodiments of the invention the preferred TiO2 content is from 0.5 to 5.5 wt. %, but a content of from 1 to 3 wt. % of TiO2 is especially preferred.


Furthermore it is preferred when at least 80%, preferably at least 95%, especially at least 99%, of the titanium dioxide content is in the +4 oxidation state. This may be achieved by oxidative melting, i.e. melting the glass batch under oxidizing conditions. Oxidative conditions during the melting can be achieved in a known way by addition of nitrates, especially of alkali nitrates, by blowing oxygen and/or dry air into the melt, or by an oxidizing burner adjustment, e.g. during melting of the glass.


Furthermore it has been shown that a possible tinting of the glass due to the TiO2 content can be reduced when chloride and/or Sb2O3 are avoided during refining. In so far as the glass contains Fe2O3, sulfate refining is preferably avoided, since the presence of sulfur-containing compounds together with iron compounds easily leads to a brown coloration. Preferably no refining agents are included in the glass and the refining is conducted e.g. by applying a low pressure, or with As2O3 and/or Sb2O3.


A reduced iron content of up to 0.2 wt. % in connection with the TiO2 content has a synergistic effect in regard to a good UV blocking. However since the danger of forming an intensely brown colored Ti/Fe complex exists, especially during extended thermal treatment of the glass, an iron content of at most 1500 ppm of Fe2O3 is preferred. For development of the synergistic effect the iron content is preferably at least 50 ppm. A Fe2O3 content of 150 to 500 ppm is preferred.


In the embodiments, in which Fe2O3 is present, it has been shown that a minimum content of TiO2 of 0.5 wt. % and especially 0.7 and/or 0.8 wt. %, is sufficient. The upper limit for the TiO2 content in the presence of Fe2O3 amounts to 4.5 wt. %, especially 4 wt. %, wherein 3.5 wt. % is particularly preferred. In many situations an upper limit of 3 wt. %, especially of 2.8 wt. % and even 2.5 wt. % has proven to be completely sufficient.


The molar ratio of Fe2O3 to titanium should preferably be greater than 1:6, especially greater than 1:22.


The borosilicate glass according to the invention can contain preferably from 0 to 3 wt. % ZrO2, from 0 to 3 wt. % WO3, from 0 to 3 wt % of Bi2O3 and from 0 to 3 wt. % of MoO3. However the amounts of the more strongly colored oxides, WO3 and MoO3, are preferably kept less than 1 wt. %.


In preferred embodiments of the invention the borosilicate glass, for example, has a composition of, in wt. % on an oxide basis, of SiO2, 69-77; B2O3, 10-12; Al2O3, 3.5-6; TiO2, 0.1-7; Na2O, 6-8; CaO, 1-2.5; Fe2O3, 0-0.2; ZrO2, 0-1 and F, 0-1.


In further preferred embodiments of the invention the borosilicate glass, for example, has a composition of, in wt. % on an oxide basis, of SiO2, 67-75; B2O3, 6-10; Al2O3, 3-7; TiO2, 0.1-7; Na2O, 5.5-8; CaO, 0.5-2; BaO, 1-3; Fe2O3, 0-0.2; ZrO2, 0-1; and F, 0-1. The preferred amount ranges for TiO2 and Fe2O3 correspond to the above-described amount ranges for these oxides.


The UV blocking obtained with these glasses is outstanding. The UV blocking at wavelengths under 260 nm is certainly fulfilled in all embodiments. Of course it is preferred that the glass can also block light in the long-wave UV range. As the examples show, it is also possible without difficulty to achieve UV blocking up to a wavelength of about 350 nm with iron-free glass compositions, and a transmission of 0.1% with a glass thickness of 1 mm.







EXAMPLE

To make examples of the borosilicate glass according to the invention a uniformly mixed glass batch of the usual raw materials was melted, refined and homogenized in a quartz glass crucible at 1600° C. Subsequently the glass melt was cast or poured and cooled with a cooling speed of 20 K/h. The following Table I shows the composition, in wt. % on an oxide basis, and essential properties of the borosilicate glass according to the present invention.


The following properties are reported in the Table:

    • glass transition temperature Tg [° C.]
    • processing temperature VA [° C. at 104 dPa s]
    • UV blocking by reporting the highest wavelength at which the transmission π amounts to a maximum of 0.1% with a sample thickness of 1 mm
    • transmission π at a wavelength of 400 nm at a sample thickness of 1 mm.









TABLE I







BOROSILICATE GLASS COMPOSITIONS OF THE INVENTION AND


THEIR PROPERTIES (OXIDE INGREDIENT AMOUNTS IN WT. %)









EXAMPLE

















Comp.
Comp.










Ex. 1
Ex. 2
1
2
3
4
5
6
7




















SiO2
74.5
68.85
74
73.7
70.5
69
74.15
72.65
70.65


B2O3
11.1
8.2
11.1
11
11.1
11.1
8.2
8.2
8.2


Al2O3
5.4
5.6
5.4
5.1
5.4
5.4
5.6
5.6
5.6


Na2O
7.3
6.5
7.3
7
7.3
7.3
6.5
6.5
6.5


K2O

1.4




1.4
1.4
1.4


MgO











CaO
1.4
1.4
1.4
1.4
1.4
1.4
1.4
1.4
1.4


SrO











BaO

2.0




2.0
2.0
2.0


F
0.25
0.25
0.30
0.25
0.20
0.20
0.25
0.25
0.25


TiO2

4.6
0.50
1.5
4
5.5
0.5
2.0
4.0


Fe3O3

1.1









MnO2

0.1









As2O3
0.05


0.05
0.1
0.1





Sum
100
100
100
100
100
100
100
100
100


τ < 0.1%,
255
351
263
286
327
349
260
293
324


nm


τ(%) at
>80
6.7
>80
>80
>80
>80
>80
>80
>80


400 nm


Tg [° C.]
559
551
558
556
559
556
553
549
550


VA [° C.]
1154
1163
1152
1150
1151
1152
1165
1167
1163


CTE
4.93
5.38
4.95
4.94
4.93
4.93
5.32
5.33
5.36


[10−6 · K−1]









The reported transmission values are for the not after-cooled sample. When the sample is heated anew during further processing, this can lead to a shift of the entire cutoff in the direction of the visible range and/or to a return of the transmission in the transitional region from the UV to the visible region.


While the invention has been illustrated and described as embodied in a borosilicate glass with UV-blocking properties for pharmaceutical packaging applications, it is not intended to be limited to the details shown, since various modifications and changes may be made without departing in any way from the spirit of the present invention.


Without further analysis, the foregoing will so fully reveal the gist of the present invention that others can, by applying current knowledge, readily adapt it for various applications without omitting features that, from the standpoint of prior art, fairly constitute essential characteristics of the generic or specific aspects of this invention.


What is claimed is new and is set forth in the following appended claims.

Claims
  • 1. A borosilicate glass with UV-blocking properties for pharmaceutical packaging, said borosilicate glass comprising, in wt. % on the basis of oxide content:
  • 2. The borosilicate glass as defined in claim 1, containing from 0.5 to 5.5 wt. % of TiO2.
  • 3. The borosilicate glass as defined in claim 1, containing from 50 ppm to 1500 ppm of Fe2O3.
  • 4. The borosilicate glass as defined in claim 1, in which at least 80% of the TiO2 present is in the +4 oxidation state.
  • 5. The borosilicate glass as defined in claim 1, which is refined with As2O3 and/or Sb2O3 as refining agent.
  • 6. The borosilicate glass as defined in claim 1, further comprising up to 1 wt. % of F.
  • 7. The borosilicate glass as defined in claim 1, wherein Fe2O3 is present and a molar ratio of Fe2O3 to TiO2 is greater than ⅙.
  • 8. The borosilicate glass as defined in claim 1, further comprising from 0 to 3 wt. % of Bi2O3, 0 to 1 wt. % of WO3, and from 0 to 1 wt. % of MoO3.
  • 9. A borosilicate glass with UV-blocking properties for pharmaceutical packaging, said borosilicate glass comprising in wt. %:
  • 10. The borosilicate glass as defined in claim 1, containing, in wt. %:
  • 11. A pharmaceutical package for a pharmaceutical preparation, said pharmaceutical package comprising a borosilicate glass with UV-blocking properties for pharmaceutical packaging, said borosilicate glass comprising, in wt. % on the basis of oxide content:
  • 12. The pharmaceutical package as defined in claim 11, wherein said borosilicate glass contains from 0.5 to 4.5 wt. % of TiO2 and from 50 ppm to 1500 ppm of Fe2O3.
Priority Claims (1)
Number Date Country Kind
10 2008 001 496 Apr 2008 DE national
US Referenced Citations (33)
Number Name Date Kind
4565791 Boudot et al. Jan 1986 A
5064461 Morena et al. Nov 1991 A
5219801 Shorrock et al. Jun 1993 A
5447891 Spinosa et al. Sep 1995 A
5459110 Brix Oct 1995 A
5610108 Watzke et al. Mar 1997 A
5612262 Kloss et al. Mar 1997 A
5747399 Kosokabe et al. May 1998 A
6204212 Kunert et al. Mar 2001 B1
6635592 Kosokabe et al. Oct 2003 B1
6851280 Ott et al. Feb 2005 B2
7375043 Fechner et al. May 2008 B2
7491668 Fechner et al. Feb 2009 B2
7700506 Fechner et al. Apr 2010 B2
20010055930 Ott et al. Dec 2001 A1
20030087745 Peuchert et al. May 2003 A1
20030184211 Hueber et al. Oct 2003 A1
20030232169 Kawai Dec 2003 A1
20040176237 Ott et al. Sep 2004 A1
20040239253 Walser et al. Dec 2004 A1
20040266603 Fechner et al. Dec 2004 A1
20050037911 Fechner et al. Feb 2005 A1
20050151116 Fechner et al. Jul 2005 A1
20060006786 Fechner et al. Jan 2006 A1
20060009343 Fechner et al. Jan 2006 A1
20060010917 Fechner et al. Jan 2006 A1
20060120105 Fechner et al. Jun 2006 A1
20060205583 Naumann et al. Sep 2006 A1
20060264313 Fechner et al. Nov 2006 A1
20080254301 Fechner et al. Oct 2008 A1
20080259602 Fechner et al. Oct 2008 A1
20100045164 Fechner et al. Feb 2010 A1
20100108914 Fechner et al. May 2010 A1
Foreign Referenced Citations (6)
Number Date Country
198 42 942 Apr 2000 DE
100 25 465 Aug 2002 DE
10 2004 027 119 Dec 2004 DE
10 2004 027 120 Dec 2004 DE
8-12369 Jan 1996 JP
2002-293571 Oct 2002 JP
Related Publications (1)
Number Date Country
20090315002 A1 Dec 2009 US